(SOLV) Solventum - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US83444M1018
Stock: Medical Devices, Dental Supplies, Software
Total Rating 37
Risk 84
Buy Signal -0.87
| Risk 5d forecast | |
|---|---|
| Volatility | 31.6% |
| Relative Tail Risk | -5.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.26 |
| Alpha | -20.76 |
| Character TTM | |
|---|---|
| Beta | 0.561 |
| Beta Downside | 0.245 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.97% |
| CAGR/Max DD | -0.19 |
EPS (Earnings per Share)
Revenue
Description: SOLV Solventum March 04, 2026
Solventum Corporation (SOLV) is a healthcare company operating in the United States and internationally. It focuses on critical customer and patient needs. The company operates in three segments: Medsurg, Dental Solutions, and Health Information Systems.
The Medsurg segment provides a range of medical and surgical supplies, including wound care, sterilization, and temperature management products. The Dental Solutions segment offers dental and orthodontic products like brackets, aligners, and restorative materials. The Health Information Systems segment delivers software solutions for healthcare systems, including computer-assisted physician documentation and coding automation. This sector typically involves long sales cycles and recurring revenue models for software services.
Solventum distributes its products and services through various channels, including direct-to-consumer, distribution networks, and e-commerce. As a healthcare equipment company, SOLV operates in a highly regulated industry with significant R&D investment. Investors may find further details on these segments and their market positions by researching SOLV on ValueRay.
Headlines to watch out for
- Medsurg product sales drive significant revenue growth
- Dental Solutions segment faces competitive market pressures
- Health Information Systems software adoption boosts profitability
- Regulatory changes impact medical device approval timelines
- Healthcare spending trends influence demand for SOLV products
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 1.56b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -5.64 > 1.0 |
| NWC/Revenue: 8.68% < 20% (prev 6.61%; Δ 2.07% < -1%) |
| CFO/TA 0.03 > 3% & CFO 369.0m > Net Income 1.56b |
| Net Debt (4.16b) to EBITDA (2.81b): 1.48 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (175.3m) vs 12m ago 0.46% < -2% |
| Gross Margin: 53.47% > 18% (prev 0.56%; Δ 5.29k% > 0.5%) |
| Asset Turnover: 57.91% > 50% (prev 57.09%; Δ 0.82% > 0%) |
| Interest Coverage Ratio: 5.94 > 6 (EBITDA TTM 2.81b / Interest Expense TTM 347.0m) |
Altman Z'' 1.84
| A: 0.05 (Total Current Assets 3.86b - Total Current Liabilities 3.14b) / Total Assets 14.29b |
| B: 0.13 (Retained Earnings 1.80b / Total Assets 14.29b) |
| C: 0.14 (EBIT TTM 2.06b / Avg Total Assets 14.38b) |
| D: 0.13 (Book Value of Equity 1.17b / Total Liabilities 9.24b) |
| Altman-Z'' Score: 1.84 = BBB |
Beneish M -3.06
| DSRI: 0.83 (Receivables 1.03b/1.23b, Revenue 8.32b/8.25b) |
| GMI: 1.04 (GM 53.47% / 55.65%) |
| AQI: 0.96 (AQ_t 0.64 / AQ_t-1 0.66) |
| SGI: 1.01 (Revenue 8.32b / 8.25b) |
| TATA: 0.08 (NI 1.56b - CFO 369.0m) / TA 14.29b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of SOLV shares?
As of March 19, 2026, the stock is trading at USD 68.67 with a total of 1,145,457 shares traded.
Over the past week, the price has changed by -0.77%, over one month by -10.43%, over three months by -16.83% and over the past year by -10.89%.
Over the past week, the price has changed by -0.77%, over one month by -10.43%, over three months by -16.83% and over the past year by -10.89%.
Is SOLV a buy, sell or hold?
Solventum has received a consensus analysts rating of 3.25.
Therefor, it is recommend to hold SOLV.
- StrongBuy: 1
- Buy: 2
- Hold: 8
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the SOLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.2 | 31.3% |
| Analysts Target Price | 90.2 | 31.3% |
SOLV Fundamental Data Overview March 19, 2026
P/E Trailing = 7.7331
P/E Forward = 10.8225
P/S = 1.4311
P/B = 2.3592
P/EG = 1.2198
Revenue TTM = 8.32b USD
EBIT TTM = 2.06b USD
EBITDA TTM = 2.81b USD
Long Term Debt = 5.04b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 5.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.16b USD (from netDebt column, last quarter)
Enterprise Value = 16.07b USD (11.91b + Debt 5.04b - CCE 878.0m)
Interest Coverage Ratio = 5.94 (Ebit TTM 2.06b / Interest Expense TTM 347.0m)
EV/FCF = -1000.0x (Enterprise Value 16.07b / FCF TTM -10.0m)
FCF Yield = -0.06% (FCF TTM -10.0m / Enterprise Value 16.07b)
FCF Margin = -0.12% (FCF TTM -10.0m / Revenue TTM 8.32b)
Net Margin = 18.69% (Net Income TTM 1.56b / Revenue TTM 8.32b)
Gross Margin = 53.47% ((Revenue TTM 8.32b - Cost of Revenue TTM 3.87b) / Revenue TTM)
Gross Margin QoQ = 49.30% (prev 56.15%)
Tobins Q-Ratio = 1.12 (Enterprise Value 16.07b / Total Assets 14.29b)
Interest Expense / Debt = 1.01% (Interest Expense 51.0m / Debt 5.04b)
Taxrate = 9.17% (157.0m / 1.71b)
NOPAT = 1.87b (EBIT 2.06b * (1 - 9.17%))
Current Ratio = 1.23 (Total Current Assets 3.86b / Total Current Liabilities 3.14b)
Debt / Equity = 1.00 (Debt 5.04b / totalStockholderEquity, last quarter 5.05b)
Debt / EBITDA = 1.48 (Net Debt 4.16b / EBITDA 2.81b)
Debt / FCF = -415.7 (out of range, set to none) (Net Debt 4.16b / FCF TTM -10.0m)
Total Stockholder Equity = 4.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.82% (Net Income 1.56b / Total Assets 14.29b)
RoE = 36.74% (Net Income TTM 1.56b / Total Stockholder Equity 4.24b)
RoCE = 22.22% (EBIT 2.06b / Capital Employed (Equity 4.24b + L.T.Debt 5.04b))
RoIC = 17.47% (NOPAT 1.87b / Invested Capital 10.71b)
WACC = 5.88% (E(11.91b)/V(16.95b) * Re(7.98%) + D(5.04b)/V(16.95b) * Rd(1.01%) * (1-Tc(0.09)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.75%
[DCF] Fair Price = unknown (Cash Flow -10.0m)
EPS Correlation: -60.73 | EPS CAGR: -17.56% | SUE: -0.21 | # QB: 0
Revenue Correlation: 39.67 | Revenue CAGR: -0.79% | SUE: 2.69 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.66 | Chg7d=+0.000 | Chg30d=+0.039 | Revisions Net=+5 | Analysts=11
EPS current Year (2026-12-31): EPS=6.47 | Chg7d=+0.000 | Chg30d=+0.131 | Revisions Net=+12 | Growth EPS=+6.0% | Growth Revenue=-2.2%
EPS next Year (2027-12-31): EPS=7.09 | Chg7d=+0.000 | Chg30d=+0.187 | Revisions Net=+9 | Growth EPS=+9.5% | Growth Revenue=+3.5%
[Analyst] Revisions Ratio: +0.56 (7 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -5.0% (Discount Rate 8.0% - Earnings Yield 12.9%)
[Growth] Growth Spread = +0.7% (Analyst -4.2% - Implied -5.0%)
P/E Forward = 10.8225
P/S = 1.4311
P/B = 2.3592
P/EG = 1.2198
Revenue TTM = 8.32b USD
EBIT TTM = 2.06b USD
EBITDA TTM = 2.81b USD
Long Term Debt = 5.04b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 5.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.16b USD (from netDebt column, last quarter)
Enterprise Value = 16.07b USD (11.91b + Debt 5.04b - CCE 878.0m)
Interest Coverage Ratio = 5.94 (Ebit TTM 2.06b / Interest Expense TTM 347.0m)
EV/FCF = -1000.0x (Enterprise Value 16.07b / FCF TTM -10.0m)
FCF Yield = -0.06% (FCF TTM -10.0m / Enterprise Value 16.07b)
FCF Margin = -0.12% (FCF TTM -10.0m / Revenue TTM 8.32b)
Net Margin = 18.69% (Net Income TTM 1.56b / Revenue TTM 8.32b)
Gross Margin = 53.47% ((Revenue TTM 8.32b - Cost of Revenue TTM 3.87b) / Revenue TTM)
Gross Margin QoQ = 49.30% (prev 56.15%)
Tobins Q-Ratio = 1.12 (Enterprise Value 16.07b / Total Assets 14.29b)
Interest Expense / Debt = 1.01% (Interest Expense 51.0m / Debt 5.04b)
Taxrate = 9.17% (157.0m / 1.71b)
NOPAT = 1.87b (EBIT 2.06b * (1 - 9.17%))
Current Ratio = 1.23 (Total Current Assets 3.86b / Total Current Liabilities 3.14b)
Debt / Equity = 1.00 (Debt 5.04b / totalStockholderEquity, last quarter 5.05b)
Debt / EBITDA = 1.48 (Net Debt 4.16b / EBITDA 2.81b)
Debt / FCF = -415.7 (out of range, set to none) (Net Debt 4.16b / FCF TTM -10.0m)
Total Stockholder Equity = 4.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.82% (Net Income 1.56b / Total Assets 14.29b)
RoE = 36.74% (Net Income TTM 1.56b / Total Stockholder Equity 4.24b)
RoCE = 22.22% (EBIT 2.06b / Capital Employed (Equity 4.24b + L.T.Debt 5.04b))
RoIC = 17.47% (NOPAT 1.87b / Invested Capital 10.71b)
WACC = 5.88% (E(11.91b)/V(16.95b) * Re(7.98%) + D(5.04b)/V(16.95b) * Rd(1.01%) * (1-Tc(0.09)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.75%
[DCF] Fair Price = unknown (Cash Flow -10.0m)
EPS Correlation: -60.73 | EPS CAGR: -17.56% | SUE: -0.21 | # QB: 0
Revenue Correlation: 39.67 | Revenue CAGR: -0.79% | SUE: 2.69 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.66 | Chg7d=+0.000 | Chg30d=+0.039 | Revisions Net=+5 | Analysts=11
EPS current Year (2026-12-31): EPS=6.47 | Chg7d=+0.000 | Chg30d=+0.131 | Revisions Net=+12 | Growth EPS=+6.0% | Growth Revenue=-2.2%
EPS next Year (2027-12-31): EPS=7.09 | Chg7d=+0.000 | Chg30d=+0.187 | Revisions Net=+9 | Growth EPS=+9.5% | Growth Revenue=+3.5%
[Analyst] Revisions Ratio: +0.56 (7 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -5.0% (Discount Rate 8.0% - Earnings Yield 12.9%)
[Growth] Growth Spread = +0.7% (Analyst -4.2% - Implied -5.0%)